2023
Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, Yildirim I, Omer S, Schulz W, Andrews J, Hitchings M, Kennedy B, Richeson R, Cummings D, Ko A. Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population. Nature Communications 2023, 14: 5055. PMID: 37598213, PMCID: PMC10439918, DOI: 10.1038/s41467-023-40750-8.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPrior infectionHybrid immunityInfection riskCOVID-19 vaccinationNon-pharmaceutical interventionsInfected residentsVaccinationInfectionDocumented exposureDelta periodCell exposureIncarcerated populationsExposureImmunityRiskAssociationPotential benefitsCorrectional facilitiesCrowded settingsResidentsPeriod
2016
Transfusion support for the oncology patient
Schulz W, Snyder E. Transfusion support for the oncology patient. 2016, 574-580. DOI: 10.1002/9781119013020.ch50.ChaptersOncology patientsTransfusion supportTransfusion-transmitted diseasesSafety of transfusionTA-GVHDTransplant patientsAdverse eventsDonor testingAppropriate therapyABO incompatibilityPatient populationTransfusion therapyOncologic disordersMajor therapyPatientsTransfusion servicesCellular antigensBlood componentsTherapyFrequent exposureTransfusionSpecific assessmentRiskAlloimmunizationImmunomodulation